Stoke Therapeutics, Inc. (STOK) Tops Q1 EPS by 2c

Stoke Therapeutics, Inc. (NASDAQ: STOK) reported Q1 EPS of ($0.79), $0.02 better than the analyst estimate of ($0.81). Revenue for the quarter came in at $6.23 million versus the consensus estimate of $7.07 million.

For earnings history and earnings-related data on Stoke Therapeutics, Inc. (STOK) click here.

You May Also Be Interested In

• Gulfport Energy and Mobility Global to join S&P SmallCap 600
• Uranium Royalty Corp. sets shareholder vote on $1.14B Sweetwater deal
• GameStop 'remains focused on advancing' proposed eBay deal, offers adjusted EBITDA guidance - Filing